Navigation Links
Tragara Pharmaceuticals' Apricoxib Reverses EMT, a Key Process for Cancer Progression and Metastasis
Date:5/26/2011

SAN DIEGO, May 26, 2011 /PRNewswire/ -- Tragara Pharmaceuticals, Inc. announced today that apricoxib (Capoxigem®, TG01), its novel COX-2 inhibitor in development for select cancer types, demonstrated reversal of the epithelial-mesenchymal transition (EMT) in xenograft models of several types of solid tumors. These data results were presented at the 2011 American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium and the 2011 American Association for Cancer Research (AACR) Annual Meeting and demonstrate that apricoxib potently inhibits the activity of COX-2 and COX-2 derived prostaglandin E2 (PGE2), which in turn mediates EMT and the associated progression and metastasis of solid tumors.

"Reversal of EMT may provide several clinical benefits to patients with non-small cell lung cancer and pancreatic cancer," stated Sara Zaknoen, M.D., chief medical officer, Tragara Pharmaceuticals, Inc. "Patients may experience longer survival due to effects of EMT reversal on metastases and the cancer stem cell, and benefit from the reversal of resistance to drugs such as erlotinib."

Tragara has completed two phase II clinical trials of apricoxib. Results from the APRiCOT-L trial, a biomarker-based, phase II, randomized, placebo-controlled study of apricoxib in combination with erlotinib in non-small cell lung cancer, will be presented on June 6th at the ASCO meeting in Chicago. A second phase II study of apricoxib in combination with gemcitabine and erlotinib has completed enrollment and is currently being analyzed.

"COX-2 has been implicated in EMT, so we were gratified to see robust reversal of EMT resulting from apricoxib treatment in xenograft models of pancreatic, colon, and head and neck cancers," stated Francis Burrows, Ph.D., head of oncology biology, Tragara Pharmaceuticals, Inc.  "This effect was associated with profound inhibition of metastasis in orthotopic cancer models but, interestingly, apricoxib-mediated EMT re
'/>"/>

SOURCE Tragara Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- Gateway Analytical announced today that they ... Annual Global Pharma Manufacturing Summit in ... The Global Pharma Manufacturing Summit offers a networking ... biologic pharmaceutical manufacturing. The conference is focused on ... such as the increasing pressure to grow and ...
(Date:8/28/2014)... Telik, Inc. (OTCQB: TELK), a clinical ... MabVax Therapeutics, Inc. on July 8, 2014, announced ... the development of its lead antibody program designated ... Company,s internally developed antibody discovery platform.  These preclinical ... based therapeutic and diagnostic products based on this ...
(Date:8/28/2014)... 2014  Rx Safes, Inc., the manufacturer of fingerprint ... waging a new war on drugs to reduce prescription ... More than 2,500 children a day experiment with ... are easily accessed from unsecured medicine cabinets, closets and drawers. ... streets, Rx Safes will address the new age drug ...
Breaking Medicine Technology:Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 2Gateway Analytical to Promote Particulate Identification Services at the 9th Annual Global Pharma Manufacturing Summit 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 2Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 3Telik Reports Progress Toward Multiple Early Stage Milestones in the Development of a Novel Antibody-based Therapeutic Agent for Gastrointestinal Cancers 4Rx Safes, Inc. Announces New War On Drugs 2
... Study of Zalutumumab in Combination, With Radiotherapy ... COPENHAGEN, June 24 Genmab A/S (OMX: GEN),announced ... zalutumumab,(HuMax-EGFr(TM)) in combination with radiotherapy for the treatment of,advanced ... maximum of 36,patients who are ineligible for platinum based ...
... New Recommendations Address Presurgery and Pediatric Dilemmas, ... evidence-based guidelines,address the prevention and management of ... related to the routine use of,preventive therapies. ... issue of CHEST,the peer-reviewed journal of the ...
Cached Medicine Technology:Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 2Genmab Initiates Study of Zalutumumab With Radiotherapy in Head and Neck Cancer 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 2Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 3Thrombosis Guidelines Emphasize Difficult Choices for Pregnant Women 4
(Date:8/28/2014)... technology advances, science has become increasingly about datahow ... The creation of key databases to analyze and ... bioinformatics , or the collection, classification, storage, and ... and software. The tools and methods used in ... fields such as molecular genetics and genomics. But, ...
(Date:8/28/2014)... FL (PRWEB) August 28, 2014 Following the ... July 21, the FDA issued a warning ... word about this harmful substance that is readily available to ... In May, high school senior Logan Stiner died from an ... of the substance, leading the FDA to issue a safety ...
(Date:8/28/2014)... place glue directly on the nerve stumps, but this ... allows glue to easily invade the nerve ends. Ordinarily, ... insert the nerve ends into the conduit because the ... Liang and co-workers from the General Hospital of Chinese ... and defined the best parameters for its use through ...
(Date:8/28/2014)... and over who identify themselves as ,old, feel worse ... they have lower value than younger age groups. , ... titled ,Being old and ill, across different countries: social ... data from the European Social Survey. Respondents, who were ... their health., The researchers found that those living in ...
(Date:8/28/2014)... (PRWEB) August 28, 2014 Canadian Linen ... company in North America, today announced the launch of ... makes doing business with Canadian Linen even easier and ... customers to access account information online and better communicate ... portal include the ability to:, , ...
Breaking Medicine News(10 mins):Health News:Together, humans and computers can figure out the plant world 2Health News:Together, humans and computers can figure out the plant world 3Health News:FDA Issues Safety Advisory for Caffeine Powders 2Health News:Canadian Linen and Uniform Service Launches New Customer Portal 2Health News:Canadian Linen and Uniform Service Launches New Customer Portal 3
... of Texas Health Science Center at Houston say one organism ... causes colic, inconsolable crying in an otherwise healthy baby. ... that comes through the door," said J. Marc Rhoads, M.D., ... at Houston, which is part of the UT Health Science ...
... , , , , ... in June, Adecco USA continues to see job opportunities for qualified professionals ... unemployment rate is over 6%, Adecco USA currently has demand for 100 ... talent for today. , , Over ...
... , , SAN FRANCISCO, July ... for the Cure, one of over 100 Affiliates nationwide dedicated to putting ... million dollars to support Bay Area breast health education and breast cancer ... Komen San Francisco Bay Area Affiliate,s local fundraising efforts, such ...
... WASHINGTON, July 24 After reviewing scientific studies of the ... of Sciences has determined there is "limited or suggestive evidence" of ... to Agent Orange. , , "We ... conclusions," said John Rowan, National President of Vietnam Veterans of America ...
... of bark with right canine expression, researcher says , FRIDAY, ... new study suggests that 6-month-old babies know the answer. , ... out that an aggressive bark goes with an angry-looking dog. ... feelings in a different way. , The babies managed to ...
... July 24 Heska Corporation (Nasdaq: HSKA ) announces the following Webcast: , ... What: Heska Corporation Invites You to Join Its Second Quarter 2009, ... the Web, When: Monday, August 10, @ 9:00 a.m. (MDT), ... the, front page of ...
Cached Medicine News:Health News:Pinpointing cause of colic: UT Houston researchers identify organism 2Health News:Wanted: Oklahoma City Licensed Pharmacy Technicians 2Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.2 Million This Year to Community Outreach Programs 2Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.2 Million This Year to Community Outreach Programs 3Health News:San Francisco Bay Area Affiliate of the Susan G. Komen for the Cure Funds Over $1.2 Million This Year to Community Outreach Programs 4Health News:Babies Can Comprehend 'Canine' Language 2Health News:Webcast Alert: Heska Announces Second Quarter 2009 Earnings Conference Call Webcast 2
... contact lenses used for corneal refractive therapy, ... The patient wears the lenses overnight while ... the day, nearsightedness is corrected or greatly ... contact lenses apply slight pressure to the ...
MDI will work with your facility to determine the best interim lab to fit your needs and your site....
... currently maintains a large number of mobile, ... in its rental fleet. The labs are ... to several years. The Cath Lab Leasing ... while replacing or upgrading existing equipment, initiating ...
... holmium laser combines excellent cutting, ablation ... bloodless procedures. It is also extremely ... bladder stones of all compositions, making ... Because its laser light is transmitted ...
Medicine Products: